首页> 美国卫生研究院文献>Japanese Journal of Clinical Oncology >A randomized double-blind non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients

【2h】

A randomized double-blind non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients

机译：盐酸氢吗啡酮速释片与盐酸羟可待酮速释粉对癌症疼痛的随机双盲非劣效性研究：对日本癌症患者的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundHydromorphone is a standard opioid analgesic for cancer pain that, prior to this study, was not approved in Japan, where options for opioid switching are limited. We aimed to investigate the efficacy and safety of hydromorphone (DS-7113b) immediate-release tablets in opioid-naïve cancer patients with moderate to severe cancer pain.

机译：背景氢吗啡酮是一种用于治疗癌症疼痛的标准阿片类镇痛药，在这项研究之前，日本尚未批准阿片类药物的选择，因为日本的阿片类药物转换选择非常有限。我们旨在研究氢吗啡酮（DS-7113b）速释片在中度至重度癌痛的无阿片类药物的癌症患者中的疗效和安全性。

著录项

期刊名称 Japanese Journal of Clinical Oncology
作者
Satoshi Inoue; Yoji Saito; Satoru Tsuneto; Etsuko Aruga; Hiroshi Takahashi; Mitsutoshi Uemori;
展开▼
作者单位

展开▼
年(卷),期 -1(48),6
年度 -1
页码 542–547
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
hydromorphone oxycodone cancer pain palliative medicine double-blind study;

机译：氢吗啡酮;羟考酮;癌痛;姑息药;双盲研究;
入库时间 2022-08-21 10:53:51

相似文献

外文文献
中文文献
专利

1. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients [J] . Inoue Satoshi, Saito Yoji, Tsuneto Satoru, Japanese journal of clinical oncology. . 2018,第6期

机译：随机，双盲，非劣液性研究对盐酸氢机即时释放片剂与羟氢酮盐酸酮肿瘤急救粉末：日本癌症患者的疗效和安全性
2. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief) [J] . Satoshi Inoue, Yoji Saito, Satoru Tsuneto, Journal of Pain Research . 2017,第6期

机译：盐酸氢吗啡酮缓释片与盐酸羟可待酮缓释片对癌症疼痛的随机，双盲研究：日本癌症患者的疗效和安全性（EXHEAL：氢吗啡酮延释氢吗啡酮用于缓解癌症疼痛的III期研究）
3. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: A phase 3, randomized, double-blind, multicenter study [J] . YuS., ShenW., YuL., The journal of pain: official journal of the American Pain Society . 2014,第8期

机译：中国癌症患者每日一次氢吗啡酮缓释与每日两次盐酸羟考酮控释的安全性和有效性：一项三期，随机，双盲，多中心研究
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. A randomized double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief) [O] . Satoshi Inoue, Yoji Saito, Satoru Tsuneto, 2017

机译：盐酸氢吗啡酮缓释片与盐酸羟可待酮缓释片对癌症疼痛的随机双盲研究：在日本癌症患者中的疗效和安全性（EXHEAL：氢吗啡酮延释氢吗啡酮用于缓解癌症疼痛的III期研究）
6. A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients [O] . Satoshi Inoue, Yoji Saito, Satoru Tsuneto, 2018

机译：随机，双盲，非劣液性研究对盐酸氢手机即时释放片剂与羟酮盐酸羟酮立即释放粉末，用于癌症疼痛：日本癌症患者的疗效和安全性

A randomized double-blind non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients

摘要

著录项

相似文献

相关主题

期刊订阅